The market is projected to expand due to new medication approvals for the treatment of ALK-positive lung cancer. In August 2018, the China National Drug Administration (CNDA) authorized F. Hoffmann-La Roche Ltd.'s Alecensa (alectinib) for the treatment of ALK-positive lung cancer. Alecensa (alectinib) was also given commercial approval by the CNDA as a single treatment for patients with anaplastic lymphoma kinase (ALK)-positive and advanced non-small cell lung cancer (NSCLC).
Rapid medication resistance is likely to hinder the growth of the ALK-positive lung cancer therapy market. According to an Oncology Live February 2018 study, fast rise of resistance is a key problem in medication development, which is accountable for poor patient recovery from illness. Furthermore, tyrosine kinase mutations and Epidermal Growth Factor Receptor (EGFR) activation are pathways for treatment resistance, according to a report published in Cancers magazine in August 2017. These resistance bypass mechanisms are worsening tumor cells, which in turn is limiting market development.
North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa make up the worldwide ALK-positive lung cancer therapy market. Because of the growing number of clinical trials in the United States, the market in North America is projected to develop significantly. For example, TP Therapeutics, Inc. is conducting a clinical trial for the TPX-0005 medication, which is designed to treat ALK mutations. The research will be completed in December 2021.